Under the agreement, Therapure will be responsible for the manufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at its facility in Mississauga, Ontario. The company will provide current good manufacturing practice biomanufacturing capabilities to advance the vaccine candidates through clinical studies.

VBI is using its enveloped virus-like particle (eVLP) platform for the development of a preventative pancoronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS), in collaboration with the National Research Council of Canada.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...